Topic Highlights

• Introduction
• Inducing Remission in Mildly-to-Moderately Active UC
• Maintaining Remission in Mildly-to-Moderately Active UC
• Summary
• CME Post-Test and Program Evaluation

Faculty/Faculty Disclosure

Russell D. Cohen, MD, FACG, AGAF
Associate Professor of Medicine
The University of Chicago Medical Center
Chicago, Illinois

Dr Cohen reports that he is a consultant to Axcan Pharma, Procter & Gamble Pharmaceuticals, Salix Pharmaceuticals, Inc., Shire US Inc., and UCB Pharma. He also serves on the speakers’ bureaus for Axcan Pharma, Procter & Gamble, Salix, Shire US, and UCB.

Bret A. Lashner, MD, MPH
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

Dr Lashner reports that he is a consultant to Abbott Laboratories, Elan Pharmaceuticals, Inc., Procter & Gamble, Shire US, and UCB.

Seymour M. Sabesin, MD
Professor of Medicine
Rush University Medical Center
Chicago, Illinois

Dr Sabesin reports that he is President of Digestive Diseases Education Company.

Philippe Vitat
Vice President
Digestive Diseases Education Company
Fishers, Indiana

Mr Vitat reports that he is Vice President of Digestive Diseases Education Company. He has no direct, relevant financial relationships, interests, or affiliations with the manufacturers of any commercial products discussed in this educational activity.

It is the policy of the Rush University Medical Center Office of Continuing Medical Education (CME) to ensure that its CME activities are independent, free of commercial bias, and beyond the control of persons or organizations with an economic interest in influencing the content of CME. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months. If there are relationships that create a conflict of interest, these must be resolved by the CME Course Director in consultation with the Office of CME prior to the participation of the faculty member in the development or presentation of course content.

Intended Audience

This educational activity is in tended for gastroenterologists and gastroenterology fellows in training programs.

Learning Objectives

Upon completing this educational activity, participants will be able to:

• Review the role of oral and/or topical preparations containing 5- aminosalicylic acid in inducing and maintaining clinical remission of inflammation in mild-tomoderate ulcerative colitis (UC)
• Understand the critical importance of maintenance therapy to preclude symptomatic relapse and complications in patients with mildly-to-moderately active UC
• Discuss strategies for improving patient adherence and maximizing clinical outcomes in mild-tomoderate UC.

Accreditation Statements

Rush University Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Rush University Medical Center designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This educational activity has been planned and implemented in accordance with the Essential Areas and Policies of the ACCME.

FDA Statement for Unapproved Drug Use

In accordance with the requirements of the US Food and Drug Administration (FDA), the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Release Date: April 2009

Expiration Date: March 31, 2010

Estimated time to complete activity: 1.0 hour

Term of Approval:

April 2009 – March 31, 2010

Copyright © 2009 Elsevier Inc.